Wissenschaftliche Publikationen Suche Suche Autor/in Forschungsgruppe Veröffentlichungsdatum Wirkungsfaktor Suchen Sortieren nach RelevanceFrom A-ZAuthored onDate/Time RangeRelease date Reihenfolge AufsteigendAbsteigend Altmueller, Janine Dr.med. (1) Daniel, Peter Prof. Dr. (1) Ittermann, Bernd Dr. (1) Kammertöns, Thomas Dr. (4) Kettenmann, Helmut Prof. Dr. (2) Kieback, Elisa Dr. (1) Kopp, Joachim Dr. (1) Ku, Min-Chi Dr. (2) Millward, Jason Dr. (1) Niendorf, Thoralf Prof. Dr. (28) Paul, Friedemann Prof. Dr. med. (3) Pezzutto, Antonio Prof. Dr. (3) Qadri, Fatimunnisa Dr. (1) Schlag, Peter M. Prof. Dr. (1) Schulz-Menger, Jeanette Prof. Dr. (6) Uckert, Wolfgang Prof. Dr. (1) Waiczies, Helmar Dr. (10) Waiczies, Sonia PD Dr. (9) Winter, Lukas Dr. (4) Wolf, Susanne Dr. (2) (-) Blankenstein, Thomas Prof. Dr. (30) (-) Willimsky, Gerald Dr. (9) (-) Experimentelle Ultrahochfeld-MR (1) Genetik metabolischer und reproduktiver Störungen (1) Magnetic Resonance (1) (-) Molekulare Immunologie und Gentherapie (31) Translationale Onkologie solider Tumore (2) 1992 (4) 1993 (7) 1994 (5) 1995 (8) 1996 (6) (-) 1997 (9) 1998 (9) 1999 (2) 2000 (8) 2001 (5) (-) 2002 (5) 2003 (9) 2004 (8) 2005 (10) 2006 (1) 2007 (5) (-) 2008 (5) 2009 (2) 2010 (7) 2011 (6) 2012 (8) (-) 2013 (13) 2014 (5) 2015 (7) 2016 (9) 2017 (9) 2018 (8) 2019 (7) 2020 (4) 2021 (4) 2022 (12) 2023 (10) 2024 (3) 32 Ergebnisse: Active Filter: Blankenstein, Thomas Prof. Dr.Willimsky, Gerald Dr.Experimentelle Ultrahochfeld-MRMolekulare Immunologie und Gentherapie 1997200220082013 Sortieren: Treffgenauigkeit Neueste nach älteste Älteste nach neueste 01. April 2002 / Trends Immunol Cross-priming versus cross-tolerance: are two signals enough? T. Blankenstein T. Schueler 03. Juni 2002 / J Exp Med Inhibition of methylcholanthrene-induced carcinogenesis by an interferon gamma receptor-dependent foreign body reaction Z. Qin H.J. Kim J. Hemme T. Blankenstein 15. Mai 2002 / Canc Res Increased tumorigenicity, but unchanged immunogenicity, of transporter for antigen presentation 1-deficient tumors Z. Qin C. Harders X. Cao C. Huber T. Blankenstein B. Seliger 15. Januar 2013 / Clin Cancer Res Molecular pathways: comparing the effects of drugs and T cells to effectively target oncogenes K. Anders T. Blankenstein 08. Februar 2013 / Mol Med High immune response rates and decreased frequencies of regulatory T cells in metastatic renal cell carcinoma patients after tumor cell vaccination H. Pohla A. Buchner B. Stadlbauer B. Frankenberger S. Stevanovic S. Walter R. Frank T. Schwachula S. Olek J. Kopp G. Willimsky C.G. Stief A. Hofstetter A. Pezzutto T. Blankenstein R. Oberneder D.J. Schendel 07. März 2013 / Blood Differently immunogenic cancers in mice induce immature myeloid cells that suppress CTL in vitro but not in vivo following transfer K. Schmidt S. Zilio J.C. Schmollinger V. Bronte T. Blankenstein G. Willimsky 05. Februar 2013 / Proc Natl Acad Sci U S A Fas expression by tumor stroma is required for cancer eradication J.J. Listopad T. Kammertoens K. Anders B. Silkenstedt G. Willimsky K. Schmidt A.A. Kuehl C. Loddenkemper T. Blankenstein 01. März 2013 / J Clin Invest Virus-induced hepatocellular carcinomas cause antigen-specific local tolerance G. Willimsky K. Schmidt C. Loddenkemper J. Gellermann T. Blankenstein 01. Mai 2013 / Canc Res Fibroblast-specific protein 1/S100A4-positive cells prevent carcinoma through collagen production and encapsulation of carcinogens J Zhang L Chen X Liu T. Kammertoens T. Blankenstein Z. Qin 15. April 2013 / Canc Cell It's the peptide-MHC affinity, stupid T. Kammertoens T. Blankenstein Seitennummerierung Aktuelle Seite 1 Seite 2 Seite 3 Seite 4 Nächste Seite Next › Letzte Seite Last »
01. April 2002 / Trends Immunol Cross-priming versus cross-tolerance: are two signals enough? T. Blankenstein T. Schueler
03. Juni 2002 / J Exp Med Inhibition of methylcholanthrene-induced carcinogenesis by an interferon gamma receptor-dependent foreign body reaction Z. Qin H.J. Kim J. Hemme T. Blankenstein
15. Mai 2002 / Canc Res Increased tumorigenicity, but unchanged immunogenicity, of transporter for antigen presentation 1-deficient tumors Z. Qin C. Harders X. Cao C. Huber T. Blankenstein B. Seliger
15. Januar 2013 / Clin Cancer Res Molecular pathways: comparing the effects of drugs and T cells to effectively target oncogenes K. Anders T. Blankenstein
08. Februar 2013 / Mol Med High immune response rates and decreased frequencies of regulatory T cells in metastatic renal cell carcinoma patients after tumor cell vaccination H. Pohla A. Buchner B. Stadlbauer B. Frankenberger S. Stevanovic S. Walter R. Frank T. Schwachula S. Olek J. Kopp G. Willimsky C.G. Stief A. Hofstetter A. Pezzutto T. Blankenstein R. Oberneder D.J. Schendel
07. März 2013 / Blood Differently immunogenic cancers in mice induce immature myeloid cells that suppress CTL in vitro but not in vivo following transfer K. Schmidt S. Zilio J.C. Schmollinger V. Bronte T. Blankenstein G. Willimsky
05. Februar 2013 / Proc Natl Acad Sci U S A Fas expression by tumor stroma is required for cancer eradication J.J. Listopad T. Kammertoens K. Anders B. Silkenstedt G. Willimsky K. Schmidt A.A. Kuehl C. Loddenkemper T. Blankenstein
01. März 2013 / J Clin Invest Virus-induced hepatocellular carcinomas cause antigen-specific local tolerance G. Willimsky K. Schmidt C. Loddenkemper J. Gellermann T. Blankenstein
01. Mai 2013 / Canc Res Fibroblast-specific protein 1/S100A4-positive cells prevent carcinoma through collagen production and encapsulation of carcinogens J Zhang L Chen X Liu T. Kammertoens T. Blankenstein Z. Qin